The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to Convene Expert Panel on Expanding Access to Peptides Amid Safety, Regulatory Debate AJMC AP's BPC 157 peptide warning skips every doctor who disagrees Seattle Red FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn FDA mulls compounding for peptides previously flagged over safety risks BioSpace